Retatrutide Bloodwork: The Triple Agonist Monitoring Guide

Your gym buddy dropped 20 kg on retatrutide in four months and says he "feels amazing." He has not done a single blood test since starting. He does not know what his liver is doing. He does not know what his thyroid is doing. He does not know that 30-40% of his weight loss might be muscle.

Retatrutide is not semaglutide with extra steps. It is a triple hormone receptor agonist that hits GLP-1, GIP, and glucagon receptors simultaneously. The glucagon component is what makes it so effective for fat loss, and it is also what makes the monitoring requirements different from any other GLP-1 drug. Your liver is working harder. Your heart rate is probably higher. Your ketone production is elevated. And if you are stacking this with AAS or MK-677, the metabolic interactions get complicated fast.

This guide covers what to test, when to test it, and what the results actually mean for someone running retatrutide in a performance context.

How retatrutide differs from semaglutide and tirzepatide

Understanding why retatrutide needs different monitoring starts with understanding how it works differently.

Semaglutide is a pure GLP-1 receptor agonist. It slows gastric emptying, suppresses appetite centrally, and improves insulin secretion. One receptor, one mechanism.

Tirzepatide is a dual agonist: GLP-1 plus GIP (glucose-dependent insulinotropic polypeptide). The GIP component adds enhanced insulin sensitivity and appears to drive greater fat loss than GLP-1 alone. Two receptors, additive benefits.

Retatrutide adds a third receptor: glucagon. This is the compound that tells your liver to release glucose, break down fat, and produce ketone bodies. In a fasted or calorie-restricted state, glucagon activation drives hepatic fatty acid oxidation at a rate that neither semaglutide nor tirzepatide can match.

The Phase 2 trial published in the New England Journal of Medicine reported 24.2% mean body weight reduction at 48 weeks with the highest dose (12 mg), compared to approximately 15-17% for semaglutide and 20-22% for tirzepatide at their respective highest approved doses (Jastreboff et al., 2023). A subsequent analysis confirmed the 48-week data and showed continued weight loss through the treatment period (Jastreboff et al., 2025).

The weight loss is impressive. But the glucagon receptor activation is what changes the monitoring equation. Your liver is being told to oxidise fat at an accelerated rate. That creates metabolic byproducts and enzyme shifts that need tracking.

The baseline panel: test before your first injection

Before you start retatrutide, you need a comprehensive baseline. This is the same panel recommended for all GLP-1 agonists, with a few additions specific to the glucagon component.

Metabolic markers:

• Fasting glucose
• HbA1c
• Fasting insulin (for HOMA-IR calculation)

Liver panel (critical for retatrutide):

• ALT
• AST
• GGT
• Total bilirubin

Pancreatic markers:

• Lipase
• Amylase

Thyroid:

• TSH
• Free T4

Lipids:

• HDL
• LDL
• Triglycerides

Kidney:

• Creatinine
• eGFR

Inflammation:

• CRP

If on TRT or AAS, also add:

• Total testosterone, free testosterone, estradiol, SHBG
• Haematocrit and haemoglobin

Liver markers: why retatrutide hits your liver differently

This is the biggest monitoring difference between retatrutide and other GLP-1 agonists.

The glucagon receptor drives hepatic fatty acid oxidation. In practical terms, retatrutide tells your liver to burn fat at an accelerated rate. A sub-study of the Phase 2 trial (the NAFLD cohort) found that retatrutide reduced liver fat content by up to 82% at 48 weeks at the highest dose, with the majority of fat reduction occurring in the first 24 weeks (Sanyal et al., 2024).

That is extraordinary. If you have any degree of fatty liver from oral steroid use, alcohol, or metabolic syndrome, retatrutide may be the most effective compound currently available for resolving it. But during the period of rapid hepatic fat clearance, your liver enzymes will shift.

What to expect on your labs

ALT and AST may rise transiently during the first 12-24 weeks as the liver processes and clears accumulated fat. This is not necessarily hepatotoxicity; it is the liver remodelling. The clinical trial data showed mild, self-resolving elevations that did not lead to drug discontinuation. However, you need to distinguish this expected elevation from actual liver damage, especially if you are running oral AAS concurrently.

GGT is your differentiation tool. If ALT/AST rise but GGT stays flat, the elevation is likely from hepatic fat clearance or muscle damage from training. If GGT rises with ALT/AST, that points to genuine hepatobiliary stress and warrants dose reduction or further investigation. For a detailed guide on differentiating liver enzyme sources, see Liver Enzymes on Steroids.

Monitoring frequency for liver markers

• Weeks 0-24: Test every 4-8 weeks. This is the period of maximal hepatic fat clearance.
• Weeks 24+: Test every 12 weeks if values have stabilised.
• If running oral AAS concurrently: Test every 4 weeks regardless of timeline.

Thyroid monitoring: the calcitonin question

All GLP-1 receptor agonists carry a black box warning about medullary thyroid carcinoma (MTC) based on rodent studies showing C-cell tumors in rats and mice. This class effect applies to semaglutide, tirzepatide, and retatrutide equally.

The relevance to humans is debated. Rodent thyroid C-cells express far more GLP-1 receptors than human C-cells, and decades of GLP-1 agonist use in diabetic populations have not produced a signal for increased MTC in humans. A large population-based study found no increased risk of thyroid cancer with GLP-1 receptor agonist use (Bezin et al., 2023). However, the cautious approach remains standard.

What to test

• TSH and free T4 at baseline and every 6 months. Retatrutide does not directly suppress thyroid function, but rapid weight loss can transiently affect thyroid hormone levels through changes in TBG (thyroid binding globulin) and deiodinase activity. If your TSH starts trending up despite stable T4, investigate further. For more on thyroid changes during weight loss and steroid use, see Thyroid Function on Steroids.

• Calcitonin is not routinely recommended for most users. However, if you have a personal or family history of MTC or MEN 2, calcitonin testing before and during GLP-1 therapy is mandatory. Elevated calcitonin (above 50 pg/mL in men, above 14 pg/mL in women) warrants specialist referral and drug discontinuation.

Pancreatic markers: when elevated lipase is not pancreatitis

GLP-1 agonists commonly elevate lipase and amylase on bloodwork. This causes a lot of unnecessary panic.

In the retatrutide Phase 2 trial, lipase elevations were reported across all dose groups. The majority were mild (less than 3x the upper limit of normal), asymptomatic, and did not progress to clinical pancreatitis. GLP-1 receptor agonists slow gastric emptying, which can cause back-pressure on the pancreatic duct, leading to enzyme leakage into the bloodstream without actual pancreatic inflammation.

How to interpret the numbers

• Lipase below 3x upper limit of normal, no symptoms: This is expected. Continue retatrutide. Retest at next scheduled bloodwork.
• Lipase 3-5x upper limit, no symptoms: Reduce dose by one titration step. Retest in 2-4 weeks.
• Lipase above 5x upper limit OR any abdominal pain/vomiting: Stop retatrutide immediately. Rule out acute pancreatitis with imaging.

The key differentiator is symptoms. Elevated lipase without epigastric pain, nausea, or vomiting is almost always benign enzyme leakage, not pancreatitis. Elevated lipase with symptoms requires urgent evaluation.

Glucose, insulin, and metabolic monitoring

Retatrutide is profoundly effective at improving glycaemic control. The Phase 2 trial included participants with type 2 diabetes, and HbA1c reductions were significant across all dose groups.

For athletes who are not diabetic, the metabolic improvements are still relevant:

• Fasting glucose typically drops into the optimal range (4.0-5.0 mmol/L) within 8-12 weeks
• Fasting insulin drops substantially, improving insulin sensitivity
• HbA1c improves even in non-diabetic individuals, reflecting better average glucose control

The MK-677 interaction

This is where retatrutide gets complicated for the bodybuilding population. Many athletes stack retatrutide for appetite suppression with MK-677 for GH secretion. The problem: MK-677 worsens insulin sensitivity and raises fasting glucose, while retatrutide improves both. These are opposing forces.

In the MK-677 two-year trial, 37% of subjects on MK-677 shifted from normal glucose into the pre-diabetic range (Nass et al., 2008). If you are running both compounds, monitor fasting glucose and insulin every 4-8 weeks. If fasting glucose exceeds 6.0 mmol/L or HOMA-IR rises above 2.5, the MK-677 dose needs to come down or be discontinued. Retatrutide is not a licence to ignore MK-677's metabolic impact.

For a deeper dive on GH-related insulin resistance, see GH and Insulin Resistance.

Heart rate: the monitoring gap nobody talks about

The glucagon receptor activation in retatrutide increases resting heart rate. A systematic review and meta-analysis of GLP-1 agonists found retatrutide increases heart rate by a mean of 3.46 bpm (95% CI: 1.74-5.18) compared to placebo, similar to semaglutide (+3.35 bpm) but higher than tirzepatide (+2.05 bpm) (Zhang et al., 2026). In the Phase 2 trial, the increase peaked at 24 weeks and declined thereafter. Some individuals experience larger increases, up to 6-7 bpm.

This matters for three reasons:

1. Athletes on trenbolone or high-dose stimulants already have elevated resting heart rates
2. The combination of retatrutide + caffeine + clenbuterol + cardio creates cumulative cardiovascular stress
3. Heart rate increases from retatrutide are dose-dependent and typically plateau after 12-16 weeks

Monitoring protocol: Check resting heart rate weekly for the first 12 weeks (morning, before coffee, lying down for 5 minutes). If resting HR consistently exceeds 90 bpm, reassess your total stimulant/drug burden.

Muscle preservation: the real risk nobody monitors properly

This is the most important section for athletes. Retatrutide produces aggressive caloric deficits through appetite suppression. Without deliberate muscle preservation strategies, a significant portion of your weight loss will be lean mass.

A DXA substudy of the Phase 2 retatrutide trial (189 participants with type 2 diabetes) found that the proportion of lean mass loss relative to total weight loss was similar to other GLP-1 therapies (Coskun et al., 2025). Retatrutide does not cause disproportionately greater muscle loss despite producing more total weight loss. But "similar proportion" still means roughly 25% of total weight lost comes from fat-free mass including skeletal muscle. In absolute terms, that can represent 6+ kg of lean tissue, comparable to a decade of aging (Locatelli et al., 2024). The semaglutide STEP 1 trial showed that up to 40% of total weight lost was lean mass (Wilding et al., 2021).

Blood markers for muscle preservation

Standard bloodwork does not directly measure muscle catabolism, but several markers provide indirect signals:

• Albumin and total protein: Declining albumin suggests inadequate protein synthesis. If albumin drops below 38 g/L during retatrutide use, you are likely undereating protein.
• Creatinine: In a muscular individual, falling creatinine over time (without improved kidney function) can indicate loss of muscle mass. Track the trend, not a single reading.
• Nitrogen balance: Not a standard blood test, but 24-hour urine nitrogen can confirm whether you are in a net catabolic state.
• DEXA scan: The gold standard. Bodyweight tells you nothing useful. A DEXA every 8-12 weeks confirms whether you are losing fat or muscle.

The protocol that preserves muscle

Community protocols for preserving lean mass on retatrutide:

1. Protein intake: Minimum 2.0-2.5 g/kg of target body weight per day. This is non-negotiable. GLP-1 agonists suppress appetite for everything, including protein. Track it deliberately.
2. Resistance training: Maintain training intensity and volume. Do not use the appetite suppression as an excuse to cut training.
3. TRT or physiological testosterone: If you are natural and running retatrutide in a deep deficit, your testosterone will drop, accelerating muscle loss. Testosterone replacement at 100-150 mg/week protects against this.
4. Titrate slowly: The community consensus for athletes is to start at 0.5 mg/week and increase by 0.5 mg every 2-4 weeks. The clinical trial sweet spot appears to be 4-8 mg/week for most users. Going straight to 12 mg maximises weight loss but also maximises lean mass risk.

Community dosing protocols: what people are actually running

The Evolutionary.org community research threads (271+ replies, 13K+ views) provide real-world dosing data that the clinical trials do not:

• Starting dose: 0.25-0.5 mg/week
• Titration: Increase 0.5 mg every 2-4 weeks based on tolerability
• Sweet spot (most users): 1.5-4 mg/week for manageable appetite suppression with minimal nausea
• Maximum (aggressive cut): 8-12 mg/week (matches highest clinical trial doses)
• Common stacks: Retatrutide + GW501516 (cardarine) for enhanced fat oxidation; retatrutide + testosterone + anavar for lean mass preservation during cut

GI side effects and blood marker implications

Nausea, vomiting, diarrhoea, and constipation are the most common side effects across all GLP-1 agonists. With retatrutide, the glucagon component can add an additional layer of GI disturbance.

If GI symptoms are persistent, check:

• Electrolytes: Vomiting and diarrhoea deplete sodium, potassium, and magnesium. Potassium and magnesium should be monitored if symptoms persist beyond the titration phase.
• Kidney function: Dehydration from persistent nausea/vomiting can reduce eGFR transiently. Ensure adequate fluid intake and retest if creatinine spikes.

The complete monitoring schedule

For the general GLP-1 monitoring framework that covers markers shared with semaglutide and tirzepatide, see GLP-1 Bloodwork.

Key takeaways

• Retatrutide is a GLP-1/GIP/glucagon triple agonist. The glucagon component is what makes it more effective than semaglutide or tirzepatide for fat loss, and it is also what makes the monitoring requirements different.
• Liver enzymes (ALT, AST, GGT) are the most important markers to track. The glucagon-driven hepatic fat clearance can cause transient elevations in the first 24 weeks. Use GGT to differentiate expected remodelling from genuine hepatotoxicity.
• Retatrutide reduced liver fat by up to 82% in the Phase 2 NAFLD cohort. If you have fatty liver from oral steroid use, this is a significant potential benefit.
• Thyroid monitoring (TSH, free T4) every 6 months. Calcitonin testing only if you have a personal or family history of medullary thyroid carcinoma.
• Elevated lipase without symptoms is expected and benign. Lipase with abdominal pain requires immediate evaluation.
• Heart rate increases 2-4 bpm on average. Monitor resting HR weekly for 12 weeks, especially if stacking with stimulants or trenbolone.
• Muscle preservation requires deliberate effort: 2.0-2.5 g/kg protein daily, maintained resistance training, and DEXA scans every 8-12 weeks. Up to 40% of weight loss can be lean mass if these are not prioritised.
• MK-677 and retatrutide have opposing effects on insulin sensitivity. Monitor fasting glucose and HOMA-IR every 4-8 weeks if stacking both.
• Community sweet spot is 1.5-4 mg/week, far below the maximum trial dose of 12 mg. Start at 0.5 mg and titrate slowly.
• Retatrutide is not approved in any country. Grey market sourcing carries contamination and potency risks identical to research peptides.

---

References

1. Jastreboff, A. M., Kaplan, L. M., Frias, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 389(6), 514-526. PubMed

2. Jastreboff, A. M., Kaplan, L. M., Frias, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2025). Retatrutide phase 2 trial: 48-week efficacy and safety in people with obesity. The Lancet Diabetes & Endocrinology. PubMed

3. Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., Haupt, A., Milicevic, Z., & Cusi, K. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30(7), 2037-2048. PubMed

4. Bezin, J., Gouverneur, A., Penichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J. L. (2023). GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care, 46(2), 384-390. PubMed

5. Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E., Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine, 149(9), 601-611. PubMed

6. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. PubMed

7. Frias, J. P., Davies, M. J., Rosenstock, J., Perez Manghi, F. C., Fernandez Lando, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. PubMed

8. Coskun, T., Wu, J., et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology. PubMed

9. Locatelli, J. C. A., et al. (2024). Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care, 47(10), 1718-1730. PubMed

10. Zhang, X., et al. (2026). Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis. European Journal of Medical Research, 31(1), 108. PubMed

11. Rosenstock, J., Frias, J., Jastreboff, A. M., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet, 402(10401), 529-544. PubMed